Andersen W A, Young D E, Peters W A, Smith E B, Bagley C M, Taylor P T
Department of Obstetrics and Gynecology, University of Virginia Medical Center, Charlottesville 22908.
Gynecol Oncol. 1989 Mar;32(3):319-22. doi: 10.1016/0090-8258(89)90632-x.
Although considerable clinical data are available to guide treatment decisions for patients with ovarian epithelial malignancies, therapy for the rare malignant mixed mesodermal (mullerian) tumor (MMMT) of the ovary is poorly studied. Ten untreated patients diagnosed with primary ovarian MMMT were managed with cis-platinum-based combination chemotherapy from 1980 to 1985. Six of the 10 patients were stage III suboptimal with evaluable residual disease; 4 of these 6 had CRs with a median duration of response of 13 months. The remaining 2 patients had PRs, of 2 and 11 months duration. Four patients had stage III optimal disease; 1 progressed at 7 months, 1 progressed at 16 months and the other 2 patients have no clinical evidence of disease at 12+ and 22+ months. Despite impressive initial response rates, survival overall was poor, with a median survival for all 10 patients of 16+ months.
尽管有大量临床数据可用于指导卵巢上皮性恶性肿瘤患者的治疗决策，但对于罕见的卵巢恶性混合性中胚叶（苗勒氏）肿瘤（MMMT）的治疗研究较少。1980年至1985年期间，对10例未经治疗的原发性卵巢MMMT患者采用了以顺铂为基础的联合化疗。10例患者中有6例为Ⅲ期次优，有可评估的残留病灶；这6例中的4例获得完全缓解，缓解期中位数为13个月。其余2例患者获得部分缓解，缓解期分别为2个月和11个月。4例患者为Ⅲ期最优疾病；1例在7个月时进展，1例在16个月时进展，另外2例患者在12 +和22 +个月时无疾病临床证据。尽管初始缓解率令人印象深刻，但总体生存率较差，10例患者的中位生存期为16 +个月。
